Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide and cardiovascular risk markers in women with PCOS and NASH
2008-006928-55Phase 4Completed
- Sponsor
- Hull University Teaching Hospitals
- Start
- Apr 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of exenatide in polycystic ovary syndrome (PCOS), metabolic dysfunction-associated steatohepatitis (MASH), endothelial dysfunction and 1 more, sponsored by Hull University Teaching Hospitals. Primary endpoint: Improvement in endothelial function. Started Apr 2009; status: completed.
02
Drugs
exenatide
03
Conditions
polycystic ovary syndrome (PCOS)metabolic dysfunction-associated steatohepatitis (MASH)endothelial dysfunctioncardiac event risk
Beyond the preview
Go deeper on 2008-006928-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006928-55.